Cochrane · systematic review · CD002795
Pharmacotherapy for post traumatic stress disorder (PTSD)
Williams, T, Phillips, NJ, Stein, DJ, et al. · Cochrane Database of Systematic Reviews · 2022 · Cochrane Library
Common Mental DisordersAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
11
No studies
3
Included studies
NR
No studies 3 · 21.4%Ungraded 0 · 0%Very low 2 · 14.3%Low 5 · 35.7%Moderate 4 · 28.6%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison 1: Alpha‐blockers versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 1: Alpha‐blockers vs placebo | no estimate extracted | NR | No studies |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 1: Alpha‐blockers vs placebo | RR 0.99 [0.91, 1.08] | 1 study · 304 participants | Moderate Downgraded: risk of bias |
Comparison 2: Antipsychotics versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 2: Antipsychotics vs placebo | RR 0.51 [0.16, 1.67] | 2 studies · 43 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 2: Antipsychotics vs placebo | RR 0.98 [0.92, 1.05] | 5 studies · 348 participants | Low Downgraded: risk of bias, imprecision |
Comparison 3: MAOIs versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 3: MAOIs vs placebo | no estimate extracted | NR | No studies |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 3: MAOIs vs placebo | RR 1.14 [0.9, 1.43] | 1 study · 37 participants | Low Downgraded: risk of bias, imprecision |
Comparison 4: NaSSAs versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ Treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 4: NaSSAs vs placebo | RR 0.45 [0.22, 0.94] | 1 study · 26 participants | Low Downgraded: risk of bias, imprecision |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 4: NaSSAs vs placebo | RR 0.87 [0.68, 1.11] | 1 study · 36 participants | Low Downgraded: risk of bias, imprecision |
Comparison 5: SNRIs versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 5: SNRIs vs placebo | no estimate extracted | NR | No studies |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 5: SNRIs vs placebo | RR 0.98 [0.88, 1.1] | 2 studies · 687 participants | Very low Downgraded: risk of bias, inconsistency |
Comparison 6: SSRIs versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 6: SSRIs vs placebo | RR 0.66 [0.59, 0.74] | 8 studies · 1078 participants | Moderate Downgraded: risk of bias |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 6: SSRIs vs placebo | RR 0.98 [0.96, 1] | 14 studies · 2399 participants | Moderate Downgraded: risk of bias |
Comparison 7: TCAs versus placebo for posttraumatic stress disorder (PTSD)
Population: adults (aged 18‐85)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) Comparison 7: TCAs vs placebo | RR 0.6 [0.38, 0.96] | 1 study · 40 participants | Low Downgraded: risk of bias, imprecision |
Treatment tolerability, as measured by Dropouts due to adverse events (acute phase) Comparison 7: TCAs vs placebo | RR 0.92 [0.81, 1.05] | 3 studies · 141 participants | Moderate Downgraded: risk of bias |